Alternative strategies

Carmignac Portfolio Merger Arbitrage Plus

Global marketSRI Fund Article 8
Share Class

LU2601234326

An active absolute return strategy focusing on merger arbitrage opportunities
  • An active merger arbitrage strategy that aims to provide positive absolute returns, with limited correlation to equity markets.
  • An alternative strategy with a socially responsible investment approach, focusing on officially announced M&A deals in the developed markets.
  • Strategy offering positive correlation with interest rates.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
3 years
Cumulative Performance since launch
+ 11.2 %
-
-
-
+ 6.0 %
From 14/04/2023
To 07/05/2025
Calendar Year Performance 2024
-
-
-
-
-
-
-
-
+ 3.9 %
+ 4.6 %
Net Asset Value
111.22 £
Asset Under Management
184 M €
Net Equity Exposure30/04/2025
77.3 %
SFDR - Fund Classification

Article

8
Data as of:  May 7, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Carmignac Portfolio Merger Arbitrage Plus fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  Apr 30, 2025.
Fund management team

Market environment

• Following on from March, April was a challenging month to manage. Most asset classes ended slightly down in a highly volatile environment. Against this backdrop, the merger arbitrage strategy once again demonstrated its resilience. The HFRX Merger Arbitrage Index posted a positive monthly performance of +0.51% (in dollar terms).• However, some spreads proved slightly more volatile than average. This was particularly true of the acquisition of Spirent Communications by US company VIavi Solution, which is still awaiting approval from the Chinese antitrust authorities. • Although China has stated that it will continue its review process as planned, the market fears opposition due to recent political tensions. These same fears are affecting the Ansys/Synopsis deal. In addition, deals currently being challenged by the US authorities, such as Surmodics, have also been more volatile in the uncertain market environment. • Despite the uncertain economic and political environment, it is important to note that there has been some bidding wars. We benefited from the improved offer from private equity firm HIG Capital for Converge Technology following interest from a third party, as well as the improved price offered by Equinox Gold for Calibre Mining. • Around 20 transactions were completed, which contributed to the narrowing of all other spreads. • Uncertainties related to the trade war launched by the Trump administration slowed M&A activity in the United States in particular. Only 13 transactions were announced, including eight in Europe and one in Asia. • We also believe it is important to highlight possible regulatory changes in the United States with the proposed ‘One Agency Act’. This bill aims to consolidate the power to enforce federal antitrust laws within the Department of Justice (DOJ), which could potentially affect companies involved in mergers and acquisitions (M&A) or under investigation or litigation by the Federal Trade Commission (FTC). • Supporters of this bill argue that dual oversight by the FTC and the DOJ is redundant and inefficient. The One Agency Act would transfer antitrust enforcement authority solely to the DOJ, eliminating the FTC's ability to bring actions under Section 5 of the FTC Act, which deals with ‘unfair methods of competition’. • This could reduce the scope of anti-competitive behaviour that can be prosecuted by the federal government. This is a proposed bill, and there are significant obstacles to its implementation.

Performance commentary

• The fund posted a positive performance during the month.• Main positive contributors to performance were: Calibre Mining, Converge Technology, Discover Financial and ChampionX. • Main detractors to performance were: Surmodics, Spirent and Ansys.

Outlook strategy

• The fund's investment ratio is 102%, up from the previous month.• With 45 positions in the portfolio, diversification remains satisfactory. • 2025 continues to look much more promising than 2024 thanks to a more favourable antitrust environment for M&A activity worldwide: the change of administration in the US following Trump's election, the publication of the Draghi report in Europe recommending the emergence of national champions to face global competition, regulators in the UK being pushed by politicians to prioritise economic activity, and the Japanese market continuing to open up to foreign capital. • Lower interest rates should also drive M&A activity in the coming quarters. • However, instability linked to the trade war launched by the Trump administration and geopolitical tensions are slowing the recovery, which is less robust than we had hoped.

Performance Overview

Data as of:  May 7, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 09/05/2025

Carmignac Portfolio Merger Arbitrage Plus Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  Apr 30, 2025.
North America39.8 %
Europe ex-EUR16.8 %
Europe EUR14.1 %
Others6.6 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  Apr 30, 2025.
Equity Investment Weight78.7 %
Net Equity Exposure77.3 %
Number of Equity Issuers41

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
The advantage of Merger Arbitrage strategy is that it carries virtually no market risk. The only associated risk is that of a deal failure. That is why our approach is very cautious on two levels: we’re very selective in choosing the deals and we aim to maintain a highly diversified portfolio.
View Fund's characteristics

Related articles

Alternative StrategyApril 14, 2025English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

Find out more
Alternative StrategyJanuary 17, 2025English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

Find out more
Alternative StrategyOctober 9, 2024English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

3 minute(s) read
Find out more
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.